Abstract

Proton therapy represents the most advanced form of radiotherapy currently available. Hepato-cellular carcinoma (HCC) has been extensively treated with proton therapy since 1983 with en-couraging results in terms of effectiveness and safety, as reported in recent research articles, systematic reviews and meta-analyses. In this report, we summarized for the first time the results of proton therapy treatment for HCC according with respect to the Barcelona Clinic Liver Cancer Staging System, the most adopted classification system for HCC which provides information on both prognostic prediction and treatment allocation.

Highlights

  • Hepatocellular carcinoma (HCC) accounts for 80%/90% of all primary liver cancers, which represent the second most common cause of cancer-related death worldwide [1]

  • How to cite this paper: Dionisi, F. and Amichetti, M. (2015) Proton Therapy Results in the Treatment of Hepatocellular Carcinoma According to the Barcelona-Clinic Liver Cancer (BCLC) Staging System

  • The main findings of these works are that the use of Proton therapy (PT) for HCC registered impressive clinical results in terms of effectiveness and safety in almost all studies

Read more

Summary

Introduction

Hepatocellular carcinoma (HCC) accounts for 80%/90% of all primary liver cancers, which represent the second most common cause of cancer-related death worldwide [1]. Proton therapy (PT) represents a unique method to deliver radiotherapy which exploits the physical properties of protons of a finite range in tissue to ensure low entrance dose and quasi-zero dose beyond the end of their path [9] These properties are suitable for HCC treatment, where the therapeutic window is narrowed by the need of a high radiation doses for tumor control in the context of a cirrhotic liver, whose tolerance to radiation is low [10]. Further refinements in class stratification or treatment allocation resulting from positive end-trials are expected in the following years It has been endorsed by both the European and the American Association for the Study of the Liver [6] [13]. We attempted to summarize the clinical results for patients treated with PT according to the BCLC Staging system (Figure 1(b))

Very Early-Early Stage
66 Gy in 10 f
G3 acute toxicities 1 G3 late skin****
G3 gastrointestinal bleed 1 G5 gastrointestinal perforation
Advanced Stage
Terminal Stage
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call